These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 16608668)

  • 21. Recognizing, reporting, and reducing adverse drug reactions.
    Brown SD; Landry FJ
    South Med J; 2001 Apr; 94(4):370-3. PubMed ID: 11332899
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Getting SMART (submission management and review tracking) drug review in the computer age.
    Flieger K
    FDA Consum; 1995 Oct; 29(8):6-9. PubMed ID: 10151839
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The FDA and drug safety: a proposal for sweeping changes.
    Furberg CD; Levin AA; Gross PA; Shapiro RS; Strom BL
    Arch Intern Med; 2006 Oct; 166(18):1938-42. PubMed ID: 17030825
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FDA reorganization inspires hope for better coordination.
    May M
    Nat Med; 2011 Sep; 17(9):1024. PubMed ID: 21900900
    [No Abstract]   [Full Text] [Related]  

  • 25. A Food and Drug Administration primer.
    Simon LS
    Arthritis Rheum; 2006 Feb; 55(1):4-8. PubMed ID: 16463403
    [No Abstract]   [Full Text] [Related]  

  • 26. Federal Drug Administration authority and the emergency nurse: implications for patient safety.
    Hackenschmidt A
    J Emerg Nurs; 2006 Oct; 32(5):449-50. PubMed ID: 16997042
    [No Abstract]   [Full Text] [Related]  

  • 27. Sweeping changes to Food and Drug Administration and drug safety regulations.
    Cross JT
    Arch Intern Med; 2007 Apr; 167(7):732. PubMed ID: 17420439
    [No Abstract]   [Full Text] [Related]  

  • 28. Avoiding the regulatory capture of the Food and Drug Administration.
    Egilman DS; Presler AH; Valentin CS
    Arch Intern Med; 2007 Apr; 167(7):732-3. PubMed ID: 17420438
    [No Abstract]   [Full Text] [Related]  

  • 29. Safety concerns at the FDA.
    Lancet; 2005 Feb 26-Mar 4; 365(9461):727-8. PubMed ID: 15733696
    [No Abstract]   [Full Text] [Related]  

  • 30. When is a medical product too risky? An interview with FDA's top drug official. Interview by Tamar Nordenberg.
    Woodcock J
    FDA Consum; 1999; 33(5):8-11, 13. PubMed ID: 10522164
    [No Abstract]   [Full Text] [Related]  

  • 31. Drugs and vaccines for the common defense: refining FDA regulation to promote the availability of products to counter biological attacks.
    Javitt GH
    J Contemp Health Law Policy; 2002; 19(1):37-116. PubMed ID: 12733223
    [No Abstract]   [Full Text] [Related]  

  • 32. Combination products regulation at the FDA.
    Lauritsen KJ; Nguyen T
    Clin Pharmacol Ther; 2009 May; 85(5):468-70. PubMed ID: 19381151
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FDA update.
    Katz R
    Epilepsy Res; 2006 Jan; 68(1):85-94. PubMed ID: 16377143
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effort to privatize drug reviews grows.
    Scott L
    Mod Healthc; 1995 Jun; 25(26):54. PubMed ID: 10143746
    [No Abstract]   [Full Text] [Related]  

  • 35. Ethical guidelines and guidelines on ethics are not the same.
    Friedman JH
    Med Health R I; 2007 Feb; 90(2):38-9. PubMed ID: 17500247
    [No Abstract]   [Full Text] [Related]  

  • 36. How are drugs approved? Part 3. The stages of drug development.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2008 Mar; 46(3):17-20. PubMed ID: 18416270
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Remarks of the Lead Deputy Commissioner of the Food and Drug Administration.
    Friedman MA
    Food Drug Law J; 1998; 53(1):19-23. PubMed ID: 11795333
    [No Abstract]   [Full Text] [Related]  

  • 38. Drug advisory committees. Getting outside advice for close calls.
    Farley D
    FDA Consum; 1995 Mar; 29(2):23-6. PubMed ID: 10172354
    [No Abstract]   [Full Text] [Related]  

  • 39. The special treatment.
    Osborne R
    Nat Biotechnol; 2008 May; 26(5):487-9. PubMed ID: 18464770
    [No Abstract]   [Full Text] [Related]  

  • 40. FDA finds new ways to speed treatment to patients.
    Flieger K
    FDA Consum; 1993 Oct; 27(8):14-8. PubMed ID: 10129048
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.